In preclinical studies p300/CBP inhibitors block the AR transcriptional program and PCa cell proliferation in cell lines as well as castration-resistant xenograft models (Jin et al. 2017, Lasko et al. 2017, Pegg et al. 2017), supporting their potential clinical impact, which needs to be further validated in clinical trials. The gene discussed is EP300; the disease is posterior cortical atrophy.